Skip to main content
Nanobiotix logo

Nanobiotix — Investor Relations & Filings

Ticker · NANO ISIN · FR0011341205 LEI · 969500667RSYIH8YL895 PA Manufacturing
Open in API
Filings indexed 791 across all filing types
Latest filing 2022-09-12 Capital/Financing Update
Country FR France
Listing PA NANO

About Nanobiotix

https://www.nanobiotix.com/

Nanobiotix is a late-stage clinical biotechnology company pioneering a physics-based approach to cancer treatment through the development of nanotherapeutics. Its lead product candidate, NBTXR3, is a potential first-in-class radioenhancer designed to be injected directly into a tumor. When activated by radiotherapy, NBTXR3 amplifies the radiation dose within the tumor, aiming to destroy cancer cells more effectively without increasing exposure to surrounding healthy tissues. This process is also intended to prime an immune response to target metastatic tumors. The company is developing NBTXR3 for broad application across various solid tumors, with an initial focus on head, neck, and lung cancers through a global licensing agreement with Janssen Pharmaceutica NV.

Recent filings

Filing Released Lang Actions
Inside Information / Other news releases
Capital/Financing Update Classification · 99% confidence The document is explicitly labeled as a "PRESS RELEASE" and announces an "agreement in principle to restructure existing loan agreement." It details financial terms, maturity dates, and expected execution timelines (Q4 2022). This type of announcement, which communicates a significant financial event (debt restructuring) outside of the standard periodic reports (like 10-K or IR), fits best under the Capital/Financing Update category (CAP). It is not a full financial report (10-K, IR), an earnings release (ER), or a management discussion (MDA). Since it directly concerns debt obligations and capital structure modification, CAP is the most appropriate classification.
2022-09-12 English
Informations privilégiées / Autres communiqués
Capital/Financing Update Classification · 99% confidence The document is titled "COMMUNIQUÉ DE PRESSE" (Press Release) and announces an agreement in principle to restructure an existing loan agreement with the European Investment Bank (EIB), extending operational capacity. This announcement concerns financing activities, capital structure, and debt restructuring. This aligns directly with the definition of 'Capital/Financing Update' (CAP). Although it discusses debt, it is an announcement about a financing agreement, not a general regulatory filing (RNS) or a formal financial report (10-K, IR). The length (9234 chars) is substantial, indicating it is the primary content, not just a brief announcement of a report (ruling 2 does not apply).
2022-09-12 French
Total number of voting rights and capital / Information on the total number of voting rights and the number of shares making up the capital
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "VOTING RIGHTS AND SHARES CAPITAL OF THE COMPANY" and explicitly references French Commercial Code articles related to the total number of voting rights and shares outstanding as of a specific date (August 31, 2022). This type of periodic disclosure, detailing the total number of shares and voting rights, is a mandatory regulatory filing in many jurisdictions, often related to capital structure transparency. It is not an AGM presentation, an earnings release, a full annual/interim report, or a director's dealing. Since it is a specific regulatory disclosure about the capital structure and voting rights, it fits best under the category for official voting results/rights announcements or as a general regulatory filing. Given the specific focus on the total number of voting rights (theoretical vs. exercisable), it aligns closely with the intent of 'Declaration of Voting Results & Voting Rights Announcements' (DVA), although it is a periodic update rather than the result of a specific vote. However, since it is a formal, periodic disclosure mandated by financial authorities (AMF), and it deals directly with voting rights structure, DVA is the most specific fit among the options provided. If DVA were strictly limited to *results* of a vote, RNS would be the fallback, but DVA covers 'Voting Rights Announcements'.
2022-09-08 English
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 95% confidence The document is titled "INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL SOCIAL" (Monthly information relating to the total number of voting rights and shares comprising the share capital). It explicitly references French regulatory articles (Code de commerce and Règlement Général de l'Autorité des Marchés Financiers - AMF) and provides a table detailing the total number of shares and voting rights as of August 31, 2022. This type of mandatory monthly disclosure regarding the share capital structure and voting rights is a specific regulatory filing in France, but among the provided codes, it most closely aligns with notifications concerning share capital changes or major shareholdings, or general regulatory announcements. Since it is a specific, recurring regulatory disclosure about the share count, it is not a general Earnings Release (ER), Interim Report (IR), or Annual Report (10-K). It is not a Director's Dealing (DIRS) or a Major Shareholding Notification (MRQ) which usually reports changes by specific entities crossing thresholds. Given the nature of mandatory disclosure on the total number of shares and voting rights, it fits best under the general regulatory announcement category, RNS, as it is a specific, recurring regulatory filing that doesn't map perfectly to the other specialized codes like DIV, CAP, or SHA (which usually implies issuance/buyback activity rather than just a monthly count). However, since it directly reports on the total number of shares, SHA (Share Issue/Capital Change) is a possibility, but RNS is safer for recurring statutory disclosures not tied to a specific transaction announcement. Re-evaluating the options: It is a statutory disclosure about the capital structure. SHA covers 'Share Issue/Capital Change'. While this is a monthly count, it is the most relevant category dealing with the composition of the capital. If SHA is interpreted broadly as 'Capital Structure Information', it fits. If we strictly adhere to the definitions, this is a mandatory regulatory filing about the capital base, making RNS the most appropriate fallback if SHA is too narrow (i.e., only for announcements of new issues/buybacks). Given the explicit focus on the total number of shares and voting rights, which is fundamental to capital structure, and the lack of a specific 'Share Capital Status Report' code, RNS (Regulatory Filings) is the most appropriate general classification for this recurring statutory disclosure.
2022-09-08 French
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is titled "COMMUNIQUÉ DE PRESSE" (Press Release) and announces a specific operational milestone: the recruitment of the first patient in Asia for the Phase 3 clinical trial NANORAY-312, involving NBTXR3 for head and neck cancers. This type of announcement, detailing progress in clinical trials, partnerships, and key operational updates, is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a formal announcement of a significant business/clinical event rather than a full financial report (10-K, IR) or a transcript (CT), and it is not specifically about management changes (MANG), director dealings (DIRS), or dividends (DIV), it fits best as an Earnings Release (ER) if it were tied to a reporting period, or a general Regulatory Filing (RNS). Given the context of biotech press releases announcing trial progress, ER is often used for such operational updates, even if not strictly quarterly earnings. However, since it is a press release announcing clinical trial progress and partnership updates, and it is not a formal financial statement, the most appropriate general category for a significant, non-standard regulatory update that isn't explicitly defined elsewhere is Regulatory Filings (RNS). Upon review, while it contains operational news, it is not a standard earnings release format (lacking key financial metrics summary). Therefore, RNS (Regulatory Filings / General Announcement) is the safest classification for a press release detailing clinical trial progress and partnership milestones that doesn't fit a more specific category like M&A or Capital Change.
2022-09-07 French
Inside Information / Other news releases
Regulatory Filings Classification · 100% confidence The document is explicitly titled "PRESS RELEASE" and announces a specific corporate event: the enrollment of the first patient in Asia for the NANORAY-312 Phase 3 trial, involving Nanobiotix and LianBio. This type of announcement, detailing clinical trial progress, partnerships, and future outlook, is characteristic of a general corporate update or press release. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a detailed management discussion (MDA). Since it is a press release announcing operational/clinical progress, it fits best under the general category for regulatory announcements that don't fit elsewhere, which is Regulatory Filings (RNS), or potentially an Investor Presentation (IP) if it were structured as slides, but as a press release, RNS is the most appropriate general classification for non-standard, timely corporate news.
2022-09-07 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.